Alzheimer’s and Tau Pathologies

1
174
views
Alzheimer’s and other tau pathologies

Normally bound to the microtubules that give neurons their structure, the protein tau becomesdetached in the brains of patients with Alzheimer’s disease. That leads to the fibrillary tangles that have become the hallmark of the disease.

Most textbooks explain that post-translational modifications, or PTMs, in the form of excessivephosphorylation trigger the formation and growth ofthese bundles. But new findings propose a subtle though crucial refinement.

Researchers from the Brain Mind Institute at the EPFL in Switzerland have discoveredthat while phosphorylation does trigger tau detachment,it doesn’t appear to promote tangle growth. It actually protects against it. Their findings offer a new perspective on the role of phosphorylation in taupathologies, while encouraging the design of therapeutics that target tau detachment.

Numerous studies have homed in on hyperphosphorylation as a trigger for taupathologies. Unfortunately, they’ve done so with relatively poor resolution. Existing tools and methods tend to blanket tau with PTMs, unable to target anysingle site independently or to introduce phosphorylationat multiple sites with precision.

The authors of the new study overcame that limitation by leveraging a chemical syntheticstrategy they’ve recently developed. The approach uses K18 as a model for the tau protein. K18 is the fragment of the protein that contains allfour repeats involved in the binding of tau to microtubules, aswell as several PTM sites linked to tau aggregation and pathology formation in Alzheimer’s disease.

By building K18 one amino acid at a time, the team could study the effects of phosphorylationat single or multiple sites on the protein. They generated K18 with 1, 2, 3 or 4 phosphorylation sites andassessed the effects of single or multiple phosphorylation on K18 aggregation, microtubulebinding and seeding activity.

They found that phosphorylation at multiple sites (state known ashyperphosphorylation) inhibits tau aggregation and binding to microtubules. Phosphorylation atserine 262 in particular appears to play a dominantrole in disrupting tau’s ability to aggregate, bind tomicrotubules, and promote microtubule polymerization.

Findings also showed that incubation of hyperphosphorylated variants of K18 did not enhanceaggregation or produce the seeding activity typically associated with tau fibrillizationin cells. Rather, it was suppressed. In fact, this activity was increasingly dulled with an uptick in the number of2 phosphorylated sites.

This stands in contrast to the prevailing hypothesis that hyperphosphorylationnecessarily leads to tau fibrillization. The team’s work suggests that some hyperphosphorylation patterns may occur after tau fibrillizationor as a cellular response to aggregation. It also underscores the critical importance of revisiting therole of phosphorylation in regulating tau’s normal functions and its role in the pathogenesisof disease.

Inhibitors of kinases that regulate phosphorylation-dependent disassociation of tau frommicrotubules could provide a viable strategy for stabilizing the native state of tau andinhibiting its aggregation.

Studies are currently underway to explore this approach and to map the different phosphorylationevents that directly or indirectly disrupt the binding of tau to microtubules.

1 COMMENT

  1. I’ve read some good stuff here. Certainly worth bookmarking for revisiting. I surprise how much effort you put to create such a wonderful informative site.

LEAVE A REPLY

Please enter your comment!
Please enter your name here